6533b871fe1ef96bd12d1c75

RESEARCH PRODUCT

Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).

Vincenzo PavonePaola GuglielmelliFrancesca PalandriPatrizio MazzaGiuseppe A. PalumboDiletta ValsecchiFrancesco MendicinoMassimo BrecciaStefana ImperaFrancesco PassamontiDaniela CilloniMarco SantoroDomenico PastoreCarmine SelleriPaola CocoMara Morelli

subject

Cancer Researchmedicine.medical_specialtyRuxolitinib8-item Morisky Medication Adherence ScalePsychometricsTreatment adherenceruxolitiniboral therapiesMedication AdherenceCohort StudiesTreatment complianceInternal medicineSurveys and QuestionnairesNitrilesmedicineHumansIn patientProspective StudiesProspective cohort studyMyelofibrosistreatment compliance8-item Morisky Medication Adherence Scale oral therapies ruxolitinib treatment compliance Adherencebusiness.industryHematologyJanus Kinase 1Janus Kinase 2Interim analysismedicine.disease8-item Morisky Medication Adherence Scale; Adherence; oral therapies; ruxolitinib; treatment compliancePyrimidinesOncologyAdherencePrimary MyelofibrosisPyrazolesObservational studybusinessmedicine.drug

description

ROMEI, a prospective, observational study in patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib in real-world practice, assesses treatment adherence based on the 8-item Morisky Medication Adherence Scale (MMAS-8). Here, we present MMAS-8 results at week 24. Overall, 101 of 188 evaluable patients completed the questionnaire at every visit (full completers). Mean (±standard deviation) total MMAS-8 scores remained stable from week 4 to week 24 in the overall population (7.54 ± 0.77 and 7.67 ± 0.70, respectively) and full completers (7.53 ± 0.79 and 7.67 ± 0.73, respectively). Rates of low (MMAS-8 ˂6) or medium (MMAS-8 ≥ 6 to ˂8) adherence were 25–40% and 26–36%, respectively. Fifty-five full completers (54%) reported ≥1 change in adherence category (improvement and/or worsening), most of which were associated with unintentional behavior. The data suggest that one-third of patients receiving ruxolitinib may be undertreated due to non-adherence, potentially undermining disease control, and indicate a need for better interventions addressing noncompliance to oral therapies.

yearjournalcountryeditionlanguage
2021-09-15Leukemialymphoma
10.1080/10428194.2021.1969388https://pubmed.ncbi.nlm.nih.gov/34521299